Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NurOwn in Early to Moderate ALS
NCT06973629Phase 3Not yet recruiting
- Sponsor
- BrainStorm Cell Therapeutics Inc.
- Start
- Jun 2025
- Primary completion
- Nov 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing NurOwn with Placebo (2 arms). Primary endpoints: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale Total Score at 24 weeks and Frequency and severity of adverse events at 48 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
MSC-NTF
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06973629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973629.